Senores Pharmaceuticals Limited has informed the Exchange regarding financial results for quarter and financial year ended March 31, 2026.

Revenue growth above 20%Profit growth above 25%Results View source PDF Explain this filing

SENORES · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.2%Reaction day

₹971.90

prior close

₹926.00

announcement price

In-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+0.2%-1.5% vs market

Pharmaceuticals peers, median of 161sector+0.4%-1.6% vs sector

On the reaction day the stock moved 1.5 pts less than Nifty Microcap 250 and 1.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.9

10m

+0.6

15m

-0.6

30m

+1.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.2+0.2-1.5+0.4-1.6

Next day

+8.1-0.1+8.2+0.0+8.0

+16.6-1.5+18.1-0.4+17.0

+8.3-1.0+9.3+0.0+8.3

+11.7-0.4+12.2+1.2+10.6

+14.0+0.6+13.4+2.0+12.0

+19.4+2.3+17.0+1.0+18.4

15d

+6.4+3.5+2.9+1.4+5.0

+31.6+5.6+26.1+2.2+29.4

+50.2+9.5+40.7+7.9+42.3

+51.4+13.3+38.1+8.1+43.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 161Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Senores Pharmaceuticals reported strong audited consolidated results for FY26 with revenue from operations growing 59% to Rs. 632.63 crore from Rs. 398.25 crore in FY25. Net profit after tax increased 53% to Rs. 137.32 crore from Rs. 89.82 crore. For Q4 FY26 standalone, revenue was Rs. 36.81 crore and PAT was Rs. 8.48 crore. The company received an unmodified audit opinion confirming clean financials. Management also announced the resignation of Company Secretary Vinay Kumar Mishra effective June 10, 2026, and appointment of Sharp & Tannan Associates as internal auditor for FY27. The company completed acquisitions of Apnar Pharma (75% stake) and Zoraya Pharmaceuticals during the year.

Likely market impact

Strong financial performance with robust revenue and profit growth reflects successful execution of expansion strategy. The clean audit opinion and improved profitability metrics are positive signals for investors. However, the upcoming resignation of the Company Secretary may create near-term compliance attention.